"El Instituto Cardiovascular de Rosario nació como una institución dedicada a la prevención y atención de enfermedades cardiovasculares de alta complejidad, habiéndose incorporado posteriormente otras especialidades afines y tecnologías dedicadas al diagnóstico, al tratamiento y al cuidado integral del paciente. En una empresa de servicios médicos asistenciales, la inmediatez entre la prestación y la percepción del servicio por parte del paciente genera una exposición permanente que exige mantener al máximo el nivel de alerta y el mantenimiento de los estándares de calidad más exigentes. Este es el compromiso de la organización."

During the past decade, Instituto Cardiovascular de Rosario conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 1 clinical trials were completed, i.e. on average, 10% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Cardiovascular de Rosario" #1 sponsor was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials, followed by "Actelion" with 2 trials sponsored, "Bayer" with 2 trials sponsored, "Abbott Medical Devices" with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Cardiovascular de Rosario" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Cardiovascular de Rosario" are "Pulmonary Arterial Hypertension" (4 trials), "Atrial Fibrillation" (2 trials), "Cachexia" (1 trials), "Coronary Artery Disease" (1 trials) and "Heart Failure" (1 trials). Many other conditions were trialed in "Instituto Cardiovascular de Rosario" in a lesser frequency.

Most popular intervention types in "Instituto Cardiovascular de Rosario" are "Drug" (8 trials), "Other" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Sotatercept" (2 trials), "AMPLATZER™ LAA Occluder" (1 trials), "Apixaban" (1 trials) and "Apixaban matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Cardiovascular de Rosario" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Instituto Cardiovascular de Rosario". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Instituto Cardiovascular de Rosario, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Cardiovascular de Rosario, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".